Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

Managing Patients with HFrEF Post-Discharge: Discussion of the Latest Evidence

Premiere Date: Monday, October 4, 2021

This activity offers CE credit for:

1. ABIM (MOC)
2. Medicine (accme)
3. Nursing (ANCC)
4. Pharmacy (acpe)
5. PA (aapa)
6. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Tuesday, October 4, 2022
Note: Credit Is No Longer Available

Faculty

Javed Butler, MD, MPH, MBA (Moderator) Patrick H. Lehan Chair in Cardiovascular Research Professor and Chairman, Department of Medicine Professor of Physiology University of Mississippi Medical Center Jackson, MS

Alanna Morris, MD, MSc, FHFSA, FACC, FAHA  Associate Professor of Medicine, Division of Cardiology Emory University School of Medicine Director of Heart Failure Research Emory University Clinical Cardiovascular Research Institute Atlanta, GA

Statement of Need

In 2021, new practice guidelines, updated clinical pathways, and a universal definitions and classification document were released to help clinicians better diagnose, stage, and manage patients with heart failure (HF). The recommendations include direction on sequencing foundational therapies and integrating the latest FDA-approved additions to the HF armamentarium – SGLT2 inhibitors and an oral sGC stimulator–for patients with HF with reduced ejection fraction (HFrEF).

In this first of two episodes in the CMEOCast HF podcast series, an expert faculty, including a member of the writing committee for several of the new guidelines, provides insightful perspectives on implementing the new recommendations in practice, including risk stratification, staging/classification, the role of biomarkers, therapeutic sequencing, relevant guidelines and study results. Additionally, faculty discuss helpful apps available for risk stratification and treatment decision-making support.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Integrate a risk stratification tool into practice for assessment of patients with HFrEF.
• Implement treatment strategies for HFrEF that reflect updated guidelines and study results.

Financial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Target Audience

Cardiologists, Primary Care Physicians, PAs, Nurse Practitioners, Nurses, Pharmacists

Credit Information

ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Butler reports that he is on the speakers bureau for AstraZeneca; Boehringer Ingelheim (BI)-Lilly Alliance; Janssen Pharmaceuticals, Inc.; and Novartis Pharmaceuticals Corporation. He is a consultant for Abbott; Adrenomed; Amgen Inc.; Applied Therapeutics; Array BioPharma Inc.; AstraZeneca; Bayer; Boehringer Ingelheim; CVRx; G3 Pharmaceuticals; Impulse Dynamics; Innolife Pharma, Inc.; Janssen Pharmaceuticals, Inc; LivaNova; Luitpold Pharmaceuticals, Inc.; Medtronic; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Relypsa, Inc.; Sequanna Medical; and Vifor Pharma, Inc..

Dr. Morris reports that she receives research support from the Association of Black Cardiologists; National Institutes of Health/National Heart Lung, and Blood Institute; and the Robert W. Woodruff Foundation, Inc. She also reports Institutional Research Support (paid to Emory University): Alnylam Pharmaceuticals; Amgen Inc.; Boston Scientific Corporation; Eidos Therapeutics; Ionis; Merck & Co., Inc.; MyoKardia, Inc.; National Heart, Lung, and Blood Institute (NHLBI); and Pfizer Inc. She is a shareholder with direct purchase with Gilead Sciences, Inc.

Warren Beckman (planning committee) has no disclosures to report.

Evan Luberger (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Jeffrey Hefland, DO (Peer Reviewer) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

CME Outfitters, LLC and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).